Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Sep 13, 2011

Premium

Expression Analysis has hired Jeff Fitzgerald as director of business development. Fitzgerald has more than ten years of sales and support experience with Affymetrix and RainDance Technologies. While at RainDance, he helped develop business opportunities in research and clinical markets through the use of the company's sequence enrichment technology in conjunction with various next-generation sequencing platforms. At his sales role at Affymetrix, he supported genome and academic research centers in the use of microarrays. Fitzgerald holds a BS in microbiology and molecular genetics from the University of Vermont.


Kevin Hrusovsky, CEO at Caliper Life Sciences, will join PerkinElmer's senior leadership team as part of a $600 million acquisition of Caliper by PE (see story, this issue). Hrusovsky has been CEO at Caliper since 2003 when the company acquired Zymark, where he was president and CEO. He has also held management positions at FMC, and EI DuPont de Nemours and has served as a board member of the Society for Laboratory Automation and Screening. He holds a BS in mechanical engineering from Ohio State University, an MBA from Ohio University, and an honorary doctorate from Framingham State University.


Brian Atwood has resigned from the board of directors at Helicos BioSciences. According to documents filed with the Securities Exchange Commission, he did not resign due to any disagreement with the company. Atwood is the cofounder of Versant Ventures, where he specializes in biotechnology investing. Previously, he was a general partner at Brentwood Venture Capital. He has also served as founder, president, and CEO of biotech company Glycomed, and as cofounder and director of Perkin Elmer/Cetus Instruments. He holds a BS from the University of California, Irvine, an MS from the University of California, Davis, and an MBA from Harvard Business School.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.